CEO Sergio Traversa purchased $418,000 of RLMD at $4.18, marking the largest insider purchase in the company's history. This move comes as the stock has crashed nearly 39% over the last 90 days, potentially signaling a bottom for the biotech.
Price context
RLMD is down 7.67% over the last five days and 13.53% over the last month, trading at $4.09, which is 48.78% below its 52-week high of $7.985.
Catalysts to watch
- •Q2 2026 earnings on 2026-08-07 (reported positive Phase 2 data and manufacturing delays).
- •Targeting an investigational new drug application filing for NDV-01 by the end of 2026.
- •Analyst consensus suggests a potential 75.58% upside based on current price targets.
Risks
- •The stock is technically oversold, which could indicate continued downside pressure.
- •Manufacturing delays have pushed the IND filing for NDV-01 to the end of 2026, extending the timeline for catalysts.
AI-generated context from public data. Not investment advice. Verify before trading.